Literature DB >> 10520976

Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.

H B Simpson1, K S Gorfinkle, M R Liebowitz.   

Abstract

BACKGROUND: We report the results of an open trial of cognitive-behavioral therapy (CBT) using exposure and ritual prevention as an adjunct to serotonin reuptake inhibitors (SRIs) in obsessive-compulsive disorder (OCD). We hypothesized that exposure and ritual prevention would significantly reduce OCD symptoms in patients who remained symptomatic despite an adequate trial of an SRI and enable patients to discontinue their medication.
METHOD: OCD patients taking an adequate dose of an SRI > or = 12 weeks who remained symptomatic (i.e., a Yale-Brown Obsessive Compulsive Scale [Y-BOCS] score > or = 16) were eligible. While taking a stable dose of an SRI, patients received 17 sessions of exposure and ritual prevention. For the intent-to-treat group, the paired t test was used to compare scores on the Y-BOCS, the National Institute of Mental Health (NIMH) Global OCD scale, the Clinical Global Impressions scale, and the Hamilton Rating Scale for Depression before and after exposure and ritual prevention.
RESULTS: Six of 7 eligible patients entered the study, and 5 completed it. All 6 improved on all OCD measures. The mean +/- SD Y-BOCS score was 23.8 +/- 2.6 prior to exposure and ritual prevention and 12.2 +/- 4.3 after it (p < .001). The mean percentage decrease on the Y-BOCS was 49% (range, 26%-61%). Patients were rated by the therapist and rated themselves as much (N = 4) or very much (N = 2) improved. Blood drug levels did not change in most patients during exposure and ritual prevention; thus, the improvement was attributed to this type of therapy. No patients discontinued their medication.
CONCLUSION: This open trial suggests that CBT using exposure and ritual prevention can lead to a significant reduction in OCD symptoms in patients who remain symptomatic despite an adequate trial of an SRI.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520976     DOI: 10.4088/jcp.v60n0904

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

Review 1.  A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.

Authors:  Dan J Stein; Nastassja Koen; Naomi Fineberg; Leonardo F Fontenelle; Hisato Matsunaga; David Osser; H Blair Simpson
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

Review 2.  Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.

Authors:  L D Kochan; A I Qureshi; B A Fallon
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

3.  An Atypical and Resistant Case of Obsessive Compulsive Disorder Responding Satisfactorily with an Unusual way of Exposure and Response Prevention Therapy.

Authors:  Kamal Nath; Robin Victor; Subrata Naskar
Journal:  J Clin Diagn Res       Date:  2016-03-01

4.  Defining cognitive-behavior therapy response and remission in pediatric OCD: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale.

Authors:  Gudmundur Skarphedinsson; Alessandro S De Nadai; Eric A Storch; Adam B Lewin; Tord Ivarsson
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-05-21       Impact factor: 4.785

Review 5.  Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; John H Krystal; Vladimir Coric
Journal:  NeuroRx       Date:  2006-01

6.  A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Deborah Roth Ledley; Jonathan D Huppert; Shawn Cahill; Donna Vermes; Andrew B Schmidt; Elizabeth Hembree; Martin Franklin; Raphael Campeas; Chang-Gyu Hahn; Eva Petkova
Journal:  Am J Psychiatry       Date:  2008-03-03       Impact factor: 18.112

7.  Latinos with obsessive-compulsive disorder: Mental healthcare utilization and inclusion in clinical trials.

Authors:  Chad T Wetterneck; Tannah E Little; Kimberly L Rinehart; Maritza E Cervantes; Emma Hyde; Monnica Williams
Journal:  J Obsessive Compuls Relat Disord       Date:  2012-01-08       Impact factor: 1.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.